2024

1. Connective tissue amyloidosis in patients referred for orthopedic surgery. CONNECT-AMY study

   Medicina Clinica, Vol. 163, Núm. 8, pp. e84-e88

2. Cost-effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalemia in patients with chronic kidney disease or heart failure in Spain

   Nefrologia, Vol. 44, Núm. 5, pp. 709-720

3. Diagnosing transthyretin amyloidosis in patients with known genetic cardiomyopathies - opportunities and open questions. Response

   Revista Espanola de Cardiologia

4. Diagnosis of transthyretin amyloidosis in patients with established cardiomyopathy

   Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 347-349

5. Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry

   European Journal of Heart Failure

6. Incidence and causes of hospitalization in patients with transthyretin (ATTR-CA) and light chain (AL-CA) cardiac amyloidosis

   Medicina Clinica, Vol. 162, Núm. 7, pp. e1-e7

7. Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure

   American Heart Journal, Vol. 267, pp. 52-61

8. Novel systematic processing of cardiac magnetic resonance imaging identifies target regions associated with infarct-related ventricular tachycardia

   Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 26, Núm. 10

9. Predicting the development of heart failure in patients with atrial fibrillation

   Revista Espanola de Cardiologia, Vol. 77, Núm. 9, pp. 720-722

10. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study

    Revista Espanola de Cardiologia

11. Prognosis after heart transplant in patients with hypertrophic and restrictive cardiomyopathy. A nationwide registry analysis

    Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 304-313

12. Prognostic impact of chronic obstructive pulmonary disease and bronchial asthma in patients with heart failure

    Revista Clinica Espanola, Vol. 224, Núm. 3, pp. 123-132

13. Prognostic value of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio in cardiac amyloidosis

    Revista Espanola de Cardiologia, Vol. 77, Núm. 8, pp. 634-644

14. Protocolized Natriuresis-Guided Decongestion Improves Diuretic Response: The Multicenter ENACT-HF Study

    Circulation: Heart Failure, Vol. 17, Núm. 1, pp. E011105

15. Reduced mitochondrial pyruvate carrier expression in hearts with heart failure and reduced ejection fraction patients: ischemic vs. non-ischemic origin

    Frontiers in Cardiovascular Medicine, Vol. 11

16. Repetitive ambulatory levosimendan as a bridge to heart transplantation

    Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 290-301

17. Review of the allocation criteria for heart transplant in Spain in 2023. SEC-Heart Failure Association/ONT/SECCE consensus document

    Revista Espanola de Cardiologia, Vol. 77, Núm. 1, pp. 69-78

18. Spanish heart transplant registry. 35th official report of the Heart Failure Association of the Spanish Society of Cardiology

    Revista Espanola de Cardiologia, Vol. 77, Núm. 11, pp. 926-935

19. Structural heart transcatheter interventions in orthotopic cardiac transplant and left ventricular assist devices recipients: A nationwide study

    International Journal of Cardiology, Vol. 413

20. Use of SGLT2i in patients with transthyretin amyloid cardiomyopathy: prevalence and safety in a Spanish prospective cohort

    Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 349-352